Albert Hartman, MD
Family Medicine · Lewiston, MENPI 1790110237
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,175 of the $32,558 with a category attached, or 89.6%. CSL Plasma Inc. accounts for 89.6% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $29,519, more than ten times the $219 reported in 2019. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $152.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Plasma Inc.$29K
- AstraZeneca$699
- AbbVie$339
- GSK$301
- Bayer$278
- Novo Nordisk$258
- plus $2K from 17 others
What the payments were for
- Consulting fees$29,17590%
- Food & beverage$3,30010%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Plasma Inc. | 34 | $29,175 |
| AstraZeneca | 40 | $699 |
| AbbVie(2 entities) | 16 | $339 |
| GSK | 19 | $301 |
| Bayer | 14 | $278 |
| Novo Nordisk | 15 | $258 |
| Gilead | 11 | $220 |
| Pfizer | 11 | $212 |
| Merck | 9 | $177 |
| Lilly USA, LLC | 8 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $112 |
| Astellas Pharma US Inc | 6 | $101 |
| Sanofi-aventis U.S. LLC | 5 | $100 |
| Abbott | 3 | $62 |
| Lundbeck LLC | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Boehringer Ingelheim | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Exact Sciences | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Amgen | 2 | $40 |
| Eisai Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$32,558 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 40 | $60,287 |
| OzempicSemaglutide | 36 | $38,678 |
| JardianceEmpagliflozin | 31 | $25,999 |
| TrulicityDulaglutide | 17 | $24,681 |
| FarxigaDapagliflozin Propanediol | 20 | $22,662 |
| KerendiaFinerenone | 20 | $17,439 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,743 |
| EntrestoSacubitril/Valsartan | 13 | $11,244 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $5,035 |
| Pregabalin | 43 | $2,023 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,788 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $1,774 |
| Atorvastatin Calcium | 162 | $1,506 |
| Oxycodone Hcl | 59 | $1,407 |
| Duloxetine Hcl | 21 | $1,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $212 | $60,28740 claims |
| Novo NordiskOzempic | $258 | $38,67836 claims |
| Boehringer IngelheimJardiance | $47 | $25,99931 claims |
| Lilly USA, LLCTrulicity | $147 | $24,68117 claims |
| AstraZenecaFarxiga | $699 | $22,66220 claims |
| BayerKerendia | $278 | $17,43920 claims |
| GSKTrelegy Ellipta | $301 | $12,74313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Lewiston
- Jeffrey MichaudLewiston$3K
- Mina AssadollahzadehLewiston$776
- Kristy Murray-PulsiferSouth Portland$55K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.